Diseases Inborn, Skin
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis (NCT03054428) | Regeneron Pharmaceuticals | 2017-03-21 |
Track Diseases Inborn, Skin automatically
Every clearance here is in the API, with alerts when new ones post.